Jane Street
CMPX icon

Jane Street’s Compass Therapeutics CMPX Stock Holding History

Jane Street’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,800
Closed -$44.8K – 11253
2025
Q3 		$44.8K Sell
12,800
-5,400
-30% -$17.1K ﹤0.01% 10380
2025
Q2 		$47.3K Sell
18,200
-24,400
-57% -$50.3K ﹤0.01% 9188
2025
Q1 		$80.9K Buy
+42,600
New +$113K ﹤0.01% 8889

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jane Street's CMPX Position: Q1 2026 in Review

Jane Street sold out of Compass Therapeutics (CMPX) in Q1 2026, closing a stake of 70,063 shares — an estimated $376K sold.

Jane Street first reported a position in CMPX in Q3 2022 and held it in 12 quarters. The position peaked at $1.25M in Q1 2023. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Jane Street reported no remaining Compass Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 70,063 Compass Therapeutics shares in Q1 2026, an estimated $376K.
  • Jane Street first reported a position in Compass Therapeutics in Q3 2022 and held it in 12 quarters.
  • Jane Street's Compass Therapeutics position peaked at $1.25M in Q1 2023.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.